Trials / Completed
CompletedNCT03480906
Eyenovia MiDD Usability Study
An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Eyenovia Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This study is to evaluate the usability and patient tolerability for microtherapeutic dosing of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Latanoprost | Latanoprost ophthalmic solution administered as a microdose spray |
| DRUG | Latanoprost | Latanoprost ophthalmic solution administered as an eyedrop |
Timeline
- Start date
- 2018-03-12
- Primary completion
- 2018-03-17
- Completion
- 2018-03-17
- First posted
- 2018-03-29
- Last updated
- 2018-07-26
Locations
1 site across 1 country: Panama
Source: ClinicalTrials.gov record NCT03480906. Inclusion in this directory is not an endorsement.